Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494802 | 0.88 | NLRP3 (0.42) | MAPK1NLRP3ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL18758397 | 0.85 | NLRP3 (0.40) | MAPK1NLRP3ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL14999743 | 0.84 | LMNA (0.42) | MAPK1SMN1; SMN2CHEK1NLRP3ALDH1A1 | |
| SCHEMBL6163037 | 0.84 | CYP4F2 (0.46) | NLRP3ALDH1A1HSD17B10L3MBTL1GAA | |
| SCHEMBL6286616 | 0.83 | GAA (0.45) | SMN1; SMN2ALDH1A1HSD17B10L3MBTL1GAA | |
| SCHEMBL16964041 | 0.83 | KMT2A (0.47) | SMN1; SMN2ALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL5151531 | 0.81 | PKM (0.42) | SMN1; SMN2CHEK1ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL27542150 | 0.80 | MAPT (0.43) | MAPK1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL1867904 | 0.80 | NLRP3 (0.54) | MAPK1SMN1; SMN2NLRP3ALDH1A1HSD17B10 | |
| SCHEMBL7880397 | 0.79 | KDM4E (0.48) | SMN1; SMN2NLRP3ALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021202900-A1 | 1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | MC2R, SLC10A1, SLC10A2 | MAPK1 1949/4885SMN1; SMN2 942/4885CHEK1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.